Key Figures
(as of 30 September 2022)
Staff | 145 |
Products in development | 14 |
Partnered products | 5 |
Clinical readouts in 2022 | 7 |
Clinical study initiations in 2022 | 3 |
Cash for operations | CHF 140.5 million |
Fully financed until | Q3 2024 |
Debt | None |
Shares outstanding | 83.6 million |
Total funds raised from investors | CHF 353.6 million |
Total funds received from partnering | CHF 337.9 million |
Potential total milestones from partners | CHF 3.3 billion |